Integral Health Asset Management LLC Acquires Shares of 200,000 Janux Therapeutics, Inc. (NASDAQ:JANX)

Integral Health Asset Management LLC purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 200,000 shares of the company's stock, valued at approximately $10,708,000. Integral Health Asset Management LLC owned 0.38% of Janux Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Barclays PLC raised its stake in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after buying an additional 144,883 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Janux Therapeutics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock valued at $937,000 after acquiring an additional 7,442 shares during the period. Avanza Fonder AB bought a new position in shares of Janux Therapeutics in the 4th quarter worth $139,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after purchasing an additional 1,095 shares during the last quarter. Finally, Chicago Capital LLC purchased a new stake in shares of Janux Therapeutics during the 4th quarter worth $230,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Price Performance

NASDAQ JANX traded up $0.65 during trading on Thursday, hitting $23.27. The company's stock had a trading volume of 1,726,553 shares, compared to its average volume of 867,192. Janux Therapeutics, Inc. has a fifty-two week low of $22.48 and a fifty-two week high of $71.71. The company has a market cap of $1.38 billion, a PE ratio of -19.89 and a beta of 3.24. The business's 50 day simple moving average is $28.89 and its 200-day simple moving average is $41.16.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the purchase, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 10,001 shares of company stock valued at $313,964. Insiders own 8.10% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Scotiabank cut their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Wedbush restated an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.